ADAPY (Adaptimmune Therapeutics) YoY EBITDA Growth: -135.11% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics YoY EBITDA Growth?

Adaptimmune Therapeutics ADAPY -19.64% YoY EBITDA Growth is -135.11% as of Jun. 2025.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Adaptimmune Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2025 was -135.11%.

Adaptimmune Therapeutics's EBITDA per Share for the three months ended in Jun. 2025 was $-0.10.

Adaptimmune Therapeutics YoY EBITDA Growth Related Terms

Adaptimmune Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics YoY EBITDA Growth Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.64 -13.14 2.60 47.48 59.10

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 382.00 73.12 -32.34 11.23 -135.11

Adaptimmune Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Adaptimmune Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.209--0.511)/ | -0.511 |
=59.10 %

Adaptimmune Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (Q: Jun. 2025 )
=(EBITDA per Share (Q: Jun. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.099-0.282)/ | 0.282 |
=-135.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -135.11% mean?
Adaptimmune Therapeutics (ADAPY) has a YoY EBITDA Growth of -135.11% as of Jun. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' YoY EBITDA Growth too high?
Adaptimmune Therapeutics' current YoY EBITDA Growth is -135.11%.
How does Adaptimmune Therapeutics' YoY EBITDA Growth compare to BCLI and APRE?
Adaptimmune Therapeutics' YoY EBITDA Growth of -135.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current YoY EBITDA Growth is -135.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current YoY EBITDA Growth of -135.11%. The current YoY EBITDA Growth is -135.11%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current YoY EBITDA Growth is -135.11% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].